An observational study in Bilateral Cataract, sponsored by Beaver-Visitec International, Inc.. Completed at 1 site in Israel. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2021-05-06.
Sponsored by Beaver-Visitec International, Inc. · Observational
The principal objective of the study is to determine the visual acuity at far, intermediate and near distances tested with optotypes at different distances from the eyes and tested with defocus addition lenses of patients implanted bilaterally with the POD 26P AY FineVision.
Secondary objective will be to test the glare and contrast sensitivity.
This study is a pilot study. As such it will recruit a limited number of patients : 20. Patients recruited will suffer from cataract, have no comorbidity, expressed the desire for spectacle independence and have realistic expectations.
Descriptive statistics will be used to determine the visual acuities at any distance. The occurence of glare and the determination of the contrast sensitivity will also be determined.
1,701 studies on the registry are indexed under Cataract; 230 are open to participants now.
This study's enrollment of 19 is below the median of 81 across 484 observational studies indexed under Cataract.
Browse Cataract studies →Beaver-Visitec International, Inc. is the lead sponsor of 36 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Cataract patients wishing high spectacle independance after the surgery
Exclusion Criteria:
Standard cataract surgery
Also known as: Physiol POD 26P AY FineVision
Visual acuity
At far, near and intermediate distance.
Time frame: 3 months
Contrast sensitivity
Assessment of the contrast sensitivity: determination of the visual acuity with low-contrast chart (Pelli Robson standard sight-chart ).
Time frame: 3 months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beaver-Visitec International, Inc.